227 related articles for article (PubMed ID: 22875093)
1. Microbleeds do not affect rate of cognitive decline in Alzheimer disease.
van der Vlies AE; Goos JD; Barkhof F; Scheltens P; van der Flier WM
Neurology; 2012 Aug; 79(8):763-9. PubMed ID: 22875093
[TBL] [Abstract][Full Text] [Related]
2. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
3. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
4. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.
van der Vlies AE; Koedam EL; Pijnenburg YA; Twisk JW; Scheltens P; van der Flier WM
Psychol Med; 2009 Nov; 39(11):1907-11. PubMed ID: 19335933
[TBL] [Abstract][Full Text] [Related]
5. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition.
Goos JD; Kester MI; Barkhof F; Klein M; Blankenstein MA; Scheltens P; van der Flier WM
Stroke; 2009 Nov; 40(11):3455-60. PubMed ID: 19762705
[TBL] [Abstract][Full Text] [Related]
6. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study.
Poels MM; Ikram MA; van der Lugt A; Hofman A; Niessen WJ; Krestin GP; Breteler MM; Vernooij MW
Neurology; 2012 Jan; 78(5):326-33. PubMed ID: 22262748
[TBL] [Abstract][Full Text] [Related]
7. Microbleeds do not affect rate of cognitive decline in Alzheimer disease.
Martinez-Ramirez S; Greenberg SM; Viswanathan A
Neurology; 2013 Mar; 80(13):1266. PubMed ID: 23530153
[No Abstract] [Full Text] [Related]
8. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
10. White matter hyperintensities and cognitive dysfunction in Alzheimer disease.
Heo JH; Lee ST; Kon Chu ; Park HJ; Shim JY; Kim M
J Geriatr Psychiatry Neurol; 2009 Sep; 22(3):207-12. PubMed ID: 19433863
[TBL] [Abstract][Full Text] [Related]
11. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
[TBL] [Abstract][Full Text] [Related]
12. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease.
Benedictus MR; Goos JD; Binnewijzend MA; Muller M; Barkhof F; Scheltens P; Prins ND; van der Flier WM
Neurobiol Aging; 2013 Nov; 34(11):2488-94. PubMed ID: 23731952
[TBL] [Abstract][Full Text] [Related]
13. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
14. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
[TBL] [Abstract][Full Text] [Related]
15. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
16. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
18. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.
Stenset V; Hofoss D; Johnsen L; Skinningsrud A; Berstad AE; Negaard A; Reinvang I; Gjerstad L; Fladby T
Acta Neurol Scand; 2008 Dec; 118(6):373-8. PubMed ID: 18510598
[TBL] [Abstract][Full Text] [Related]
19. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
[TBL] [Abstract][Full Text] [Related]
20. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
